Is NfL the New 'N' in A/T/N Classification of Alzheimer’s?
People with a lot of neurofilament light protein are more likely to develop mild cognitive impairment in the next four years.
ALL NEWS
384 RESULTS
Sort By:
- Most Recent
- Most Commented
Amyloid PET Aids Diagnosis. But Could CSF Do Just as Well?
Large IDEAS data set establishes that PET scans are valuable in clinical practice. Other studies suggest CSF biomarker ratios perform nearly as well.
It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline
Scientists at CTAD were excited about postmortem validation of tau scans and new, more sensitive tracers. Others are exploring practical applications for live imaging of tau pathology.
Blood Tests for Amyloid Step Out at CTAD
With plasma tests performing in AIBL staging, scientists are sharing data across platforms and cohorts, and tackling standardization to avoid time lost to irreproducibility.
NfL in Blood Foretells Poor Brain Health After the Heart Stops
Neurofilament light protein in the serum registers the degree of axonal damage after cardiac arrest, and may help doctors predict long-term consequences for the brain.
Do African-Americans Have More, or Different, Alzheimer’s Disease? Too Little Data to Tell
At a workshop on engaging more black Americans in ADRD research, new CSF findings stood out against a general dearth of data on Alzheimer’s disease in underrepresented minorities.
Alzheimer’s Researchers Seek Advice on How to Include African-Americans
Despite having a higher incidence of Alzheimer’s or a related dementia, relatively few black people participate in research studies or drug trials. How to achieve full representation?
In DIAN, Serial and Cross-Sectional Biomarker Trajectories Diverge
Serial data establishes different trajectories for CSF t-tau and p-tau.
Flortaucipir Imaging Distinguishes Alzheimer’s From Other Disorders
A large multicenter study confirms the tau PET ligand identifies AD at the dementia stage, but not so well at prodromal stages.
Flortaucipir Meets Primary Endpoints in Phase 3 Autopsy Trial
PET tracer predicts tau pathology and AD, according to company press release.
Does Retinal Thinning Reflect Early Alzheimer’s?
Study links changes in the retina’s microvasculature to brain amyloid in cognitively normal adults.
For the Faint of Heart: Doc, Want to Check Their NfL?
What's the use of measuring neurofilament light in blood? The marker could help with AD trial enrollment and measuring drug effects. It could even guide brain-sparing improvements in heart surgery, say researchers at AAIC 18.
Blood Test for Neurofilament Light Chain Kicks Up Biomarker Research
With buckets of new data at AAIC, blood NfL grabbed attention as a telltale of neurodegeneration. The protein predicts progression, and might one day track treatment effects.
With Sudden Progress, Blood Aβ Rivals PET at Detecting Amyloid
At AAIC, competitors vied for advantage, and discussion moved swiftly to the issue of assay standardization.
Memory Slips as Soon as Amyloid Appears, Two Decades Before Dementia
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
Current Filters
- Biomarkers x